Not just therapy, cultural care – a different approach to rare diseases
Profile: Todor Kesimov graduated from Regent’s Business School London in 2007. He joined the biopharmaceutical company Takeda in 2012 as a business controller for Bulgaria, and a year later he headed Finance and Logistics for Romania and Bulgaria. In the period 2017-2018 he was the head of the company’s financial department for the Balkans. From the beginning of 2018 he will take over the position of Manager of the Takeda Representative Office in Bulgaria.
Takeda is one of the oldest and fastest growing pharmaceutical companies in the world. Founded in Japan in 1781, we now operate in more than 80 countries around the world. Today we are a world leader in drugs for rare diseases. We only want to deliver not only medicines that meet the immediate needs of patients around the world, but also to provide medical care and support.
Mr. Kesimov, what are the priorities of Takeda in the care of patients with rare diseases in Bulgaria?
We are actively working in several directions along with the development and timely provision of drug treatment:
– Ensuring timely and accurate diagnosis, which is key in rare diseases. The problem here is that any other condition, being rare, affects a number of people, is not appropriate, often the clinical practice at the meeting of most doctors, and the irregular examination, which can be misdiagnosed in patients. Thus, the diagnosis is delayed for years until it has already progressed. And in most cases of rare diseases are genetically acquired, ie. with the right approach (training, screening) they could be diagnosed at an early age. Takeda works actively in the patient with all leading experts and organizations to support the earliest possible diagnosis.